SS6. Natural History of Medically-Managed Acute Type B Aortic Dissections  by Durham, Christopher A. et al.
JOURNAL OF VASCULAR SURGERY
24S Abstracts June Supplement 2014General Health Physicians, Lancaster, Pa; 3Department of
Biostatistics, University of Nebraska Medical Center,
Omaha, Neb; 4Experimental Immunology Laboratory,
Veterans Affairs Nebraska-Western Iowa Health Care
System (VA NWIHCS), Omaha, Neb; 5Experimental
Immunology Laboratory, University of Nebraska
Medical Center, Department of Internal Medicine,
Division of Rheumatology, Omaha, Neb; 6Experimental
Immunology, Research in Cardiovascular Disease
Laboratory at the University of Nebraska Medical
Center, Department of Internal Medicine, Division of
Cardiology, Omaha, Neb
Objectives: Abdominal aortic aneurysm (AAA) is a
pathologic dilation of the aorta. Inﬂammation of the aortic
wall has been shown to be involved in AAA formation.
Malondialdehyde-acetaldehyde (MAA) adducts are
MAA/protein hybrids with immunogenic, proinﬂamma-
tory, and proﬁbrotic properties. Levels of MAA adducts
are elevated in patients with coronary artery disease; how-
ever, the role of MAA adducts in AAA is unclear. We hy-
pothesize that levels of circulating antibodies against
MAA adducts are increased in patients with AAA.
Methods: Plasma samples were collected from mice
and patients with and without AAA. AAA was induced in
mice by a standard CaCl2 protocol, with matching sham
mice. Plasma levels of anti-MAA antibodies were quantiﬁed
by enzyme-linked immunosorbent assay.
Results: Patients with AAA exhibited higher levels of
immunoglobulin G (IgG) and IgA anti-MAA antibody
subtypes (P ¼ .049 and P ¼ .026, respectively) compared
with control patients. Conversely, IgM anti-MAA anti-
bodies in AAA patients were lower compared with control
patients (P ¼ .018). In CaCl2 treated mice IgG anti-MAA
antibodies were elevated after AAA formation (P ¼ .006).
Conclusions: The pattern of anti-MAA antibodies is
able to distinguish between patients with AAA and patients
with atherosclerosis but no AAA. These results demon-
strate that MAA adducts are associated with AAA and sug-
gest they may play a role in either initiating or propagating
chronic inﬂammation in AAA.
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Objectives: Although medical management of un-
complicated acute type B aortic dissections remains thestandard of care, contemporary data regarding the natural
history of medically treated patients are sparse. The goal
of this study was to evaluate the ability of medical therapy
to prevent long-term complications in patients with acute
type B aortic dissection.
Methods: All patients with acute uncomplicated Type
B aortic dissection that were initially managed medically
between March 1999 and March 2011 were included. Fail-
ure of medical therapy was deﬁned as any death or aortic-
related intervention. Early failure occurred #15 days of
presentation and late failure occurred thereafter. Predictors
of long-term outcomes were determined using Cox pro-
portional hazards models.
Results: A total of 298 patients (61.7%) with medically
managed acute type B dissections were identiﬁed. The
cohort was an average age of 65.9 years at presentation.
There were 37 early failures (12%) including 12 deaths
and 25 interventions (10 thoracic endovascular aortic repair
[TEVAR]/15 open). Aneurysmal degeneration was the
indication for intervention in six (24%). Mean follow-up
was 4.2 years (range, 0.1-14.7 years). There were 174 fail-
ures (58.4%), including 87 deaths and 87 interventions
(24 TEVAR/63 open). Fifty-seven interventions (66%)
were for aneurysmal degeneration. Freedom from interven-
tion was 77.3%6 0.024% at 3 years and 74.2%6 0.025% at
6 years. There were no predictors of freedom from interven-
tion. The intervention-free survival was 55.0% 6 0.030% at
3 years and 41.0% 6 0.032% at 6 years. Age >70 years was
protective against failure (hazard ratio, 0.97; conﬁdence in-
terval, 0.95-0.98, P < .01). Survival was higher in patients
who required intervention at both 3 years (78% vs 73%)
and 6 years (76% vs 58%; P ¼ .018).
Conclusions: Medical therapy of acute uncomplicated
type B dissections is successful in the short-term. However,
theoverall 6-year intervention-free survival is low, and survival
is signiﬁcantly higher in patients who undergo intervention.
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